Hemodynamic effects of infused arginine vasopressin in congestive heart failure

The hemodynamic effects of exogenously administered arginine vasopressin were assessed in 11 patients with chronic congestive heart failure. Infusion rates of 0.1 to 0.8 pmol/kg per min increased plasma arginine vasopressin from 6.5 +/- 2.7 (SD) pg/ml at control to 63 +/- 39 pg/ml at the highest infusion rate. There were progressive decreases in cardiac output and stroke volume, with increases in systemic vascular resistance and pulmonary capillary wedge pressure, but only minimal changes in heart rate and blood pressure. Changes in cardiac output, stroke volume and systemic resistance were evident from the first infusion rate, which increased plasma arginine vasopressin from 6.5 +/- 2.7 to 9.9 +/- 4.6 pg/ml. A paired analysis of baseline hemodynamic data with those measured during infusions producing an arginine vasopressin level averaging 15 +/- 2.6 pg/ml yielded the following changes: cardiac output decreased from 4.6 +/- 1.2 to 4.2 +/- 0.96 liters/min (p less than 0.01), stroke volume decreased from 60 +/- 19 to 54 +/- 16 ml (p less than 0.005) and systemic vascular resistance increased from 1,329 +/- 396 to 1,443 +/- 395 dynes X s X cm-5 (p = 0.01). Thus, small increases in circulating arginine vasopressin cause modest but significant adverse circulatory effects in patients with congestive heart failure. A fall in cardiac output, probably as a result of increased afterload, is seen at levels of arginine vasopressin within the basal range found in congestive heart failure. These data demonstrate that circulating arginine vasopressin in physiologic concentrations is capable of influencing hemodynamics in patients with congestive heart failure and suggest that therapy for this condition directed at inhibition of the vascular effect of arginine vasopressin may be potentially useful.

This article has been cited by other articles:

				E. S. Potapenko, V. C. Biancardi, R. M. Florschutz, P. D. Ryu, and J. E. Stern Inhibitory-excitatory synaptic balance is shifted toward increased excitation in magnocellular neurosecretory cells of heart failure rats J Neurophysiol, September 1, 2011; 106(3): 1545 - 1557. [Abstract] [Full Text] [PDF]

				B. R. Szwejkowski, S. Rekhraj, and A. Struthers 15 Vasopressin Oxford Textbook of Heart Failure, January 1, 2011; 1(1): med-9780199577729-chapter - med-9780199577729-chapter. [Abstract] [Full Text]

				K. Chatterjee Analytic Review: Hyponatremia in Heart Failure J Intensive Care Med, November 1, 2009; 24(6): 347 - 351. [Abstract] [PDF]

				J. J. Finley IV, M. A. Konstam, and J. E. Udelson Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia Circulation, July 22, 2008; 118(4): 410 - 421. [Full Text] [PDF]

				S. R. Goldsmith and M. Gheorghiade Vasopressin Antagonism in Heart Failure J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791. [Abstract] [Full Text] [PDF]

				P. Sanghi, B. F. Uretsky, and E. R. Schwarz Vasopressin antagonism: a future treatment option in heart failure Eur. Heart J., March 2, 2005; 26(6): 538 - 543. [Abstract] [Full Text] [PDF]

				J. F. Price, J. A. Towbin, S. W. Denfield, S. Clunie, E.O. Smith, C. J. McMahon, B. Radovancevic, and W. J. Dreyer Arginine Vasopressin Levels Are Elevated and Correlate With Functional Status in Infants and Children With Congestive Heart Failure Circulation, June 1, 2004; 109(21): 2550 - 2553. [Abstract] [Full Text] [PDF]

				G. S. Francis and W. H. W. Tang Vasopressin Receptor Antagonists: Will the "Vaptans" Fulfill Their Promise? JAMA, April 28, 2004; 291(16): 2017 - 2018. [Full Text] [PDF]

				S. R. Goldsmith Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res, April 1, 2002; 54(1): 13 - 15. [Full Text] [PDF]

				L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]

				A. Tahara, Y. Tomura, K.-i. Wada, T. Kusayama, J. Tsukada, N. Ishii, T. Yatsu, W. Uchida, and A. Tanaka Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte Cardiovasc Res, April 1, 1998; 38(1): 198 - 205. [Abstract] [Full Text] [PDF]

				A. Tahara, Y. Tomura, K.-I. Wada, T. Kusayama, J. Tsukada, M. Takanashi, T. Yatsu, W. Uchida, and A. Tanaka Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 301 - 308. [Abstract] [Full Text]

				S. Zhang, Y. Hirano, and M. Hiraoka Arginine Vasopressin Induced Potentiation of Unitary L-Type Ca2+ Channel Current in Guinea Pig Ventricular Myocytes Circ. Res., April 1, 1995; 76(4): 592 - 599. [Abstract] [Full Text]